Grünenthal GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.grunenthal.com
A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT03761407
- Locations
- 🇫🇷
ASTER, Paris, France
Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Grünenthal GmbH
- Registration Number
- NCT03749733
- Locations
- 🇲🇽
Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico
A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 265
- Registration Number
- NCT03745404
Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 106
- Registration Number
- NCT03737656
- Locations
- 🇲🇽
Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico
Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 1151
- Registration Number
- NCT03714672
- Locations
- 🇲🇽
University, San Luis Potosí, Mexico
🇲🇽Private Clinic, Puebla, Mexico
A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced
Not Applicable
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 107
- Registration Number
- NCT03688880
- Locations
- 🇩🇪
010 - Charité Berlin, Berlin, Germany
🇪🇸022 - Hospital General Universitario Gregorio Maranon, Madrid, Spain
🇫🇷004 - CHU Amiens-Picardie, Amiens, France
Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 267
- Registration Number
- NCT03560986
- Locations
- 🇸🇰
SK402 - MUDr. Beata Dupejova, neurologicka ambulancia sro, Banska Bystrica, Slovakia
🇺🇸US410 - Alliance Research Centers, Laguna Hills, California, United States
🇺🇸Us414 - Alexander Ford Md, Los Angeles, California, United States
Efficacy and Safety of Intravenous Neridronic Acid in CRPS
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 182
- Registration Number
- NCT03530345
- Locations
- 🇺🇸
US013 - Inland Pain Medicine, Colton, California, United States
🇺🇸US052 - Providere' Research Inc., West Covina, California, United States
🇺🇸US020 - SIMEDHealth, Ocala, Florida, United States
A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade
Phase 1
Terminated
- Conditions
- Interventions
- Combination Product: Neosaxitoxin combined with bupivacaine low (T2)Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrine (T1)Drug: Neosaxitoxin (T3)Combination Product: Bupivacaine low combined with epinephrine (C1)Combination Product: Neosaxitoxin combined with epinephrine (T4)Drug: Bupivacaine low (C3)Drug: Bupivacaine high (C4)Combination Product: Bupivacaine high combined with epinephrine (C2)Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrineCombination Product: Neosaxitoxin combined with bupivacaine low
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Grünenthal GmbH
- Target Recruit Count
- 242
- Registration Number
- NCT03399435
- Locations
- 🇳🇱
NL001, Groningen, Netherlands
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Grünenthal GmbH
- Registration Number
- NCT03137017
- Locations
- 🇺🇸
US001: PRA Health Sciences, Lenexa, Kansas, United States
© Copyright 2024. All Rights Reserved by MedPath